ライフサイエンスコーパス: isocitrate

1 dehydrogenase (carboxylation of alpha-KG to isocitrate).

2 uppressed by providing the aconitase product isocitrate.

3 is much more sensitive to concentrations of isocitrate.

4 Here, we report 2-vinyl-d-isocitrate (2-VIC) as a mechanism-based inactivator of M

5 arboxylic acid cycle intermediates (citrate, isocitrate, 2-oxoglutarate, succinate, fumarate, malate,

6 Exogenous isocitrate abrogated the erythroid iron restriction resp

7 f the erythroid iron restriction response by isocitrate administration corrected anemia and erythropo

8 DH1 and IDH2 catalyze the interconversion of isocitrate and 2-oxoglutarate (2OG).

9 extension in C. elegans, reversibly converts isocitrate and acetyl-CoA to succinate, malate, and CoA.

10 ttributed to the competitive binding between isocitrate and alphaKG, which is made more favorable for

11 The mitochondrial export of isocitrate and engagement with cytosolic isocitrate dehy

12 se assays demonstrated the presence of eight isocitrate and four AMP binding sites for the wild-type

13 Mtb's ICLs are catalytically bifunctional isocitrate and methylisocitrate lyases required for grow

14 ction, with the ability to form alphaHG from isocitrate and NADP(+).

15 the chiral imidazolium hosts toward citrate, isocitrate and the two enantiomers of malate have been s

16 ta, whose activities were regulated by iron, isocitrate, and erythropoietin.

17 mmonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and alp

18 yglutarate, citrate, oxaloacetate, pyruvate, isocitrate, and lactate using a 8-min run time in cancer

19 noise for citrate and an 8-fold increase for isocitrate as compared to detection of the untagged anal

20 Feeding of isocitrate as well as the nonmetabolizable citrate analo

21 ing it to react with carbon dioxide and form isocitrate, as occurs in the wild-type enzyme.

22 dictions that the enzyme would contain eight isocitrate binding sites, four NAD(+) binding sites, and

23 Cys-150 residues and to half-site binding of isocitrate, but that a form of negative cooperativity ma

24 pathway, involving the mitochondrial citrate/isocitrate carrier and the cytosolic NADP-dependent isoc

25 siRNA-mediated suppression of ICDc, citrate/isocitrate carrier, or Kv2.2 expression impaired GSIS, a

26 Isotope tracing revealed that in spheroids, isocitrate/citrate produced reductively in the cytosol c

27 odel in which a key function of the pyruvate-isocitrate cycle is to maintain levels of Kv2.2 expressi

28 Recent studies have shown that the pyruvate-isocitrate cycling pathway, involving the mitochondrial

29 agogues, involving flux through the pyruvate/isocitrate cycling pathway.

30 Here we demonstrate that pyruvate-isocitrate cycling regulates expression of the voltage-g

31 direction of the normal reaction (alphaKG to isocitrate), dead-end inhibition studies suggest that wi

32 harboring a mutation in the gene coding for isocitrate dehydrogenase ( IDH).

33 tion cryo-EM structures of the cancer target isocitrate dehydrogenase (93 kDa) and identify the natur

34 ase and to stimulate the reverse reaction of isocitrate dehydrogenase (carboxylation of alpha-KG to i

35 of isocitrate and engagement with cytosolic isocitrate dehydrogenase (ICDc) may be one key pathway,

36 ate carrier and the cytosolic NADP-dependent isocitrate dehydrogenase (ICDc), is involved in control

37 (via isocitrate lyase) or the TCA cycle (via isocitrate dehydrogenase (ICDH) activity) and we sought

38 Mutant isocitrate dehydrogenase (IDH) 1 and 2 proteins alter th

39 1 and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody-base

40 associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arg

41 Cit2 and reduced expression of NAD-specific isocitrate dehydrogenase (Idh) and aconitase (Aco1) in p

42 Mutations in isocitrate dehydrogenase (IDH) are the most prevalent ge

43 by the discovery of mutations involving the isocitrate dehydrogenase (IDH) enzymes.

44 activity for grading and characterization of isocitrate dehydrogenase (IDH) gene mutation status of g

45 ne promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined.

46 Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequen

47 Somatic mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur

48 expression of ATP-citrate synthase (ACS) and isocitrate dehydrogenase (IDH) genes in cold-treated tom

49 discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical

50 terozygous mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) in subsets of cancers, in

51 Isocitrate dehydrogenase (IDH) is a reversible enzyme th

52 Among a number of novel genes, isocitrate dehydrogenase (IDH) is recurrently mutated in

53 stigation of metabolic pathways disturbed in isocitrate dehydrogenase (IDH) mutant tumors revealed th

54 er, accuracy was poorer when tumors harbored isocitrate dehydrogenase (IDH) mutations (91% in IDH-wil

55 Background Isocitrate dehydrogenase (IDH) mutations are highly freq

56 s caused by recurrent mutations, such as the isocitrate dehydrogenase (IDH) mutations found in 15% of

57 Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the met

58 ation in a subset of glioblastomas harboring isocitrate dehydrogenase (IDH) mutations, but metabolic

59 associated with MYC signaling, but not with isocitrate dehydrogenase (IDH) mutations, suggesting a d

60 that shows how robust behavior arises in the isocitrate dehydrogenase (IDH) regulatory system of Esch

61 ally available MRI parameters for predicting isocitrate dehydrogenase (IDH) status in patients with g

62 drogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challengin

63 role is to consume acetyl-CoA, which unlocks isocitrate dehydrogenase (IDH)-dependent reductive carbo

64 We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combini

65 determine whether MRI/CT analysis identifies isocitrate dehydrogenase (IDH)-mutant gliomas misassigne

66 ta-N-acetylglucosamine transferase (OGT) and isocitrate dehydrogenase (IDH).

67 ide adenine dinucleotide phosphate-dependent isocitrate dehydrogenase (IDH)1 and IDH2 frequently aris

68 Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at th

69 y, we explored the function of mitochondrial isocitrate dehydrogenase (IDH)2, a tricarboxylic acid cy

70 atio and inhibits expression and activity of isocitrate dehydrogenase (IDH); and, via 13C-labeling st

71 imaging-defined invasive phenotypes of both isocitrate dehydrogenase (IDH-1)-mutated and IDH-1 wild-

72 Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recen

73 utarate (2HG), generated by mutated forms of isocitrate dehydrogenase (IDH1 and IDH2), reduces the ex

74 Mutations in the cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDH1) occur in several types o

75 rboxylated by the NADPH-linked mitochondrial isocitrate dehydrogenase (IDH2) to form isocitrate, whic

76 Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequ

77 tive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) was recen

78 We found recurrent isocitrate dehydrogenase 1 (IDH1) and IDH2 (28%) gene mu

79 Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the

80 1 was exclusive to tumors carrying wild-type isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and was

81 Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been ide

82 sue of Blood, Shi et al describe the role of isocitrate dehydrogenase 1 (idh1) and idh2 in developmen

83 Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer st

84 Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydro

85 Monoallelic point mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) and its mitochondrial

86 Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found i

87 Mutations at the arginine residue (R132) in isocitrate dehydrogenase 1 (IDH1) are frequently identif

88 Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) are key drivers of hem

89 Here, we characterize isocitrate dehydrogenase 1 (IDH1) as a transcriptional t

90 in HuR-deficient PDAC cell lines identified isocitrate dehydrogenase 1 (IDH1) as the sole antioxidan

91 Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)

92 Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently

93 Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the producti

94 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversib

95 vosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for t

96 grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggr

97 Mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

98 Gain-of-function mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

99 The recent identification of isocitrate dehydrogenase 1 (IDH1) gene mutations in glio

100 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number

101 Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGG

102 Two mutant forms (R132H and R132C) of isocitrate dehydrogenase 1 (IDH1) have been associated w

103 Isocitrate dehydrogenase 1 (IDH1) is mutated in various

104 Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as t

105 anscripts were found in GBMs irrespective of isocitrate dehydrogenase 1 (IDH1) mutation status.

106 se dependent, acted synergistically with the isocitrate dehydrogenase 1 (IDH1) mutation, and resemble

107 Absence of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic

108 Isocitrate dehydrogenase 1 (IDH1) mutations occur in app

109 Isocitrate dehydrogenase 1 (IDH1) mutations occur in mos

110 Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gl

111 letion) and mutations in the metabolic genes isocitrate dehydrogenase 1 (IDH1) or IDH2(1,2), were sha

112 exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2.

113 dromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of whi

114 Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial h

115 The human, cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) reversibly converts is

116 we performed genome-wide target profiling of isocitrate dehydrogenase 1 (IDH1), a novel RBP.

117 Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by

118 Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in g

119 One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in m

120 se reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1).

121 that can modulate the activity of the enzyme isocitrate dehydrogenase 1 (IDH1).

122 ydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme.

123 oblastomas are characterized by mutations in isocitrate dehydrogenase 1 (IDHmut).

124 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key

125 Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer

126 zygously expressed single-point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respect

127 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been disc

128 Mutations in the genes encoding isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a var

129 Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in sever

130 aking is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are

131 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present i

132 Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development

133 d ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2, respectively.

134 ers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-kappaB pathway, an

135 Isocitrate dehydrogenase 1 mutations drive human gliomag

136 rganization 2007 tumor grade, histology, and isocitrate dehydrogenase 1 R132H mutational status.

137 ssigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched w

138 ade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor sam

139 With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high

140 D-2-hydroxyglutarate imaging is possible in isocitrate dehydrogenase 1-mutated human glioma by using

141 Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in u

142 e (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was repor

143 Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG islan

144 d hematopoietic differentiation in AML after isocitrate dehydrogenase 1/2 mutation and 2-hydroxygluta

145 levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations.

146 g genetic anchor to drive patient selection (isocitrate dehydrogenase 1/2, Enolase 2).

147 pecies (ROS) by deacetylating and activating isocitrate dehydrogenase 2 (IDH2) and superoxide dismuta

148 We show that downregulation of isocitrate dehydrogenase 2 (IDH2) and TET family enzymes

149 Mitochondrial isocitrate dehydrogenase 2 (IDH2) converts NADP(+) to NA

150 The mitochondrial matrix protein isocitrate dehydrogenase 2 (IDH2) is a major source of N

151 cute myeloid leukemia (AML) treated with the isocitrate dehydrogenase 2 (IDH2) mutant-specific inhibi

152 ochondrial superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) observed in untreated

153 Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in approximately

154 Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers,

155 ons in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2

156 Isocitrate dehydrogenase 2 (IDH2) was identified as a to

157 and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (IDH2), commonly found in acu

158 tly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased

159 antioxidant system through the regulation of isocitrate dehydrogenase 2 (Idh2).

160 of unfavorable outcome, such as mutations in isocitrate dehydrogenase 2 (IDH2-R172) and overexpressio

161 rate-limiting tricarboxylic acid cycle (TCA) isocitrate dehydrogenase 2 and superoxide dismutase 2, c

162 findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 via the mitochondrial recruit

163 which in turn decreased expression of IDH2 (isocitrate dehydrogenase 2).

164 nd that the aberrant expression of wild-type isocitrate dehydrogenase 3alpha (IDH3alpha), a subunit o

165 rogenase, 2-oxoxglutarate dehydrogenase, and isocitrate dehydrogenase activities of the Krebs cycle i

166 hypoxia elicited both aconitase and NADP(+)-isocitrate dehydrogenase activity losses.

167 Hepatic isocitrate dehydrogenase activity was also decreased, wh

168 ssion changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enh

169 lternative CAM cycle involving mitochondrial isocitrate dehydrogenase as a potential contributor to i

170 was consistent with allosteric inhibition of isocitrate dehydrogenase by P-enolpyruvate.

171 al water-saving effect of carbon fixation by isocitrate dehydrogenase can reach 11% total water savin

172 e production of 2-hydroxyglutarate by mutant isocitrate dehydrogenase enzymes, we can observe metabol

173 Mechanistically, isocitrate dehydrogenase expression and the production o

174 with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a

175 Mutations in the isocitrate dehydrogenase genes (IDH1/2) occur often in d

176 glioma-associated mutations into the NADP(+ )isocitrate dehydrogenase genes (IDP1, IDP2, IDP3) in Sac

177 Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among t

178 occurring mutations in the NADP(+)-dependent isocitrate dehydrogenase genes IDH1 and IDH2 These mutat

179 e chromatin architecture at the promoters of isocitrate dehydrogenase genes to promote transcription

180 Here, we report that the isocitrate dehydrogenase IDH1 is the most strongly upreg

181 .35 million compounds against mutant (R132H) isocitrate dehydrogenase IDH1 led to the identification

182 Ps harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displaye

183 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

184 Isocitrate dehydrogenase is mutated at a key active site

185 hosphorylation catalyzed by the bifunctional isocitrate dehydrogenase kinase/phosphatase (IDHKP), and

186 The mass spectra also indicate the isocitrate dehydrogenase mutation status of the tumor vi

187 anine-DNA methyltransferase-methylation, and isocitrate dehydrogenase mutation status, the proportion

188 prognostic and therapeutic consequences: (a) isocitrate dehydrogenase mutation; (b) the combined loss

189 features or genetic alterations, except for isocitrate dehydrogenase mutations (IDH(mut)) that were

190 t developments and implications in regard to isocitrate dehydrogenase mutations in chondrosarcoma, a

191 at might be relevant in cancer cells bearing isocitrate dehydrogenase mutations.

192 tumor morphologic characteristics predicted isocitrate dehydrogenase status in World Health Organiza

193 Isocitrate dehydrogenase subunits Idh1p and Idh2p were a

194 glutarate in cells results from mutations to isocitrate dehydrogenase that correlate with cancer.

195 hat specifically binds an epitope of mutated isocitrate dehydrogenase type 1 (IDH1R132H), which is fr

196 c MRI were retrospectively selected (36 with isocitrate dehydrogenase wild-type [IDH(wt)], 16 with mu

197 ylic acid cycle (oxoglutarate dehydrogenase, isocitrate dehydrogenase) and glycine decarboxylase.

198 ytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of g

199 hydrogenase alpha levels and lower levels of isocitrate dehydrogenase, both proteins involved in the

200 ccinate dehydrogenase, fumarate hydratase or isocitrate dehydrogenase, can dysregulate specific 2OGDD

201 glutarate (catalyzed by reverse flux through isocitrate dehydrogenase, IDH).

202 search terms were used: IDH, IDH1, IDH2, and isocitrate dehydrogenase, in conjunction with glioma or

203 -(13)C]oxaloacetate to generate (13)CO(2) at isocitrate dehydrogenase, or decarboxylation of [1-(13)C

204 ein, and in the phosphorylation cycle of the isocitrate dehydrogenase, respectively.

205 rom alpha-ketoglutarate (alpha-KG) by mutant isocitrate dehydrogenase, whereas l-(S)-2-HG is generate

206 tly map to genes for aconitate hydratase and isocitrate dehydrogenase, which are expected to alter ce

207 Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce

208 Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25

209 ptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants.

210 Recently, it was shown that somatic isocitrate dehydrogenase-1 (IDH1) mutations, frequently

211 metabolism was highly dependent on cytosolic isocitrate dehydrogenase-1 (IDH1), because the activity

212 This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is a

213 Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common driver

214 lignancies owing to somatic mutations in the isocitrate dehydrogenase-1 or -2 (IDH1 or IDH2) genes, o

215 hmdC levels were independent of mutations in isocitrate dehydrogenase-1.

216 The development of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mu

217 ients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur

218 Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of

219 pment of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mutations has been described

220 ticipation of concurrent NADPH sources (i.e. isocitrate dehydrogenase-2, malic enzymes, and glutamate

221 insulin secretion is amplified by cytosolic isocitrate dehydrogenase-dependent transfer of reducing

222 Previous studies have shown that mutant isocitrate-dehydrogenase (mIDH)1/2 glioma cells convert

223 Isocitrate-dehydrogenase mutations (OR = 2.52, p = 0.026

224 Isocitrate dehydrogenases (IDH) convert isocitrate to al

225 scribed metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase

226 drug strategies and single-gene mutations in isocitrate dehydrogenases (IDH1/2).

227 Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high le

228 in arginine N-methyltransferases (PRMTs) and isocitrate dehydrogenases (IDHs), and highlight the most

229 e FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs

230 Mutations in isocitrate dehydrogenases 1 and 2 (IDH(mut)) are present

231 Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have b

232 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur

233 omatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).

234 n the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights th

235 tions in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several

236 CMA degrades isocitrate dehydrogenases IDH1 and IDH2 and reduces leve

237 lic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently

238 d outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetical

239 and the expression and activity of TETs and isocitrate dehydrogenases in primary human chondrocytes.

240 Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate

241 is high in venous plasma from patients with isocitrate dehydrogenases1 (IDH1) mutations.

242 expressing R172K mutant IDH2 did not display isocitrate-dependent NADPH production above vector contr

243 cells and retained the wild-type ability for isocitrate-dependent NADPH production.

244 DP(+)-dependent oxidative decarboxylation of isocitrate (ICT) to alpha-ketoglutarate (alphaKG) and th

245 e reversible NADP(+)-dependent conversion of isocitrate (ICT) to alpha-ketoglutarate (alphaKG) in the

246 ly catalyse the oxidative decarboxylation of isocitrate into alpha-ketoglutarate (alphaKG).

247 of aconitase, which isomerizes citrate into isocitrate, is controlled by several transcriptional reg

248 tol, imidazole, uridine diphosphate glucose, isocitrate, lactate, and fucose).

249 Isocitrate lies at one of the key nodes of carbon metabo

250 Genes encoding isocitrate lyase (aceA) and malate synthase (aceB), both

251 Isocitrate lyase (ICL) is a peroxisomal glyoxylate cycle

252 at the first enzyme of the glyoxylate shunt, isocitrate lyase (ICL), may mediate survival of Mtb duri

253 Isocitrate lyase (ICL, types 1 and 2) is the first enzym

254 ose-1,6-bisphosphatase 1) and ICL1 (encoding isocitrate lyase 1) are under control of the Mig1 repres

255 Activity of isocitrate lyase AceA, an S-allylmercapto-modified candi

256 eling is mediated by the bifunctional enzyme isocitrate lyase acting in a noncanonical role distinct

257 ssion of the latent infection genes encoding isocitrate lyase and alpha-crystallin, respectively.

258 Enzyme assays validated the increase in isocitrate lyase and malate synthase activities.

259 In this study the genes encoding isocitrate lyase and malate synthase from Chlorogloeopsi

260 Transcript abundances for isocitrate lyase and malate synthase increased, and C. f

261 When the genes encoding isocitrate lyase and malate synthase were expressed in S

262 ve expression of the glyoxylate shunt genes (isocitrate lyase and malate synthase) was >300-fold high

263 Previous studies reported the activities of isocitrate lyase and malate synthase, the key enzymes of

264 ural rearrangement, substantially increasing isocitrate lyase and methylisocitrate lyase activities.

265 w that two additional gluconeogenic enzymes, isocitrate lyase and phosphoenolpyruvate carboxykinase,

266 with PR genes and highest expression of the isocitrate lyase gene coinciding with highest solar irra

267 Isocitrate lyase is important for lipid utilisation by M

268 three enzymes are: trace levels of OGDH, the isocitrate lyase of the glyoxylate shunt and an unantici

269 , a member of the phosphoenolpyruvate mutase/isocitrate lyase superfamily, catalyzes the hydrolysis o

270 tumefaciens BlcR is a member of the emerging isocitrate lyase transcription regulators that negativel

271 Mutants of the glyoxylate shunt gene for isocitrate lyase were able to grow in the presence of oi

272 n feed into either the glyoxylate shunt (via isocitrate lyase) or the TCA cycle (via isocitrate dehyd

273 sphosphatase (FBPase), malate dehydrogenase, isocitrate lyase, and phosphoenolpyruvate carboxykinase

274 s in central carbon metabolism, specifically isocitrate lyase, malate synthase, transaldolase, fructo

275 d inhibits the growth of bacteria expressing isocitrate lyase, such as Salmonella enterica and Mycoba

276 Methylobacterium extorquens AM1, which lacks isocitrate lyase, the key enzyme in the glyoxylate cycle

277 ic acid is an organic compound that inhibits isocitrate lyase, the key enzyme of the glyoxylate shunt

278 An isocitrate lyase-deficient mutant of Mtb (Deltaicl1) exh

279 Isocitrate lyase-dependent production of succinate affor

280 all three drugs trigger activation of Mtb's isocitrate lyases (ICLs), metabolic enzymes commonly ass

281 s (Mtb) more profoundly than deletion of its isocitrate lyases (ICLs).

282 Notably, increased isocitrate (p = 1.2 x 10(-3)), but reduced citrate (p =

283 rebs cycle intermediates, including citrate, isocitrate, succinate, and malate (1.4-3.9-fold).

284 c malate than with the trianionic citrate or isocitrate, suggesting that the smaller guest is better

285 dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to alpha-ketoglutarate (alpha-KG) and reduce

286 Isocitrate dehydrogenases (IDH) convert isocitrate to alpha-ketoglutarate (alpha-KG).

287 IDH1 and IDH2 to catalyze the conversion of isocitrate to alpha-ketoglutarate (alphaKG), whereas con

288 e dehydrogenase 1 (IDH1) reversibly converts isocitrate to alpha-ketoglutarate (alphaKG).

289 ldtype function of the enzyme (conversion of isocitrate to alpha-ketoglutarate) while conferring a ne

290 bolic break at Idh, the enzyme that converts isocitrate to alpha-ketoglutarate, providing mechanistic

291 is prevents the oxidative decarboxylation of isocitrate to alpha-KG, and facilitates the conversion o

292 ctions, as well as the coupled conversion of isocitrate to alphaHG.

293 we have detailed the kinetics of the normal (isocitrate to alphaKG) and neomorphic (alphaKG to alphaH

294 onitase-mediated isomerization of citrate to isocitrate; trans-aconitate, but not its methyl ester, i

295 t enzyme) demonstrated half-site binding for isocitrate (two sites) in the absence of dithiothreitol

296 lactate, alanine, glycerol-3 phosphate, and isocitrate were significantly associated with higher T2D

297 biomarkers-formate, citrulline, taurine, and isocitrate-were identified as markers of SSB intake.

298 strate the present approach with citrate and isocitrate, which are isomeric metabolites each containi

299 ng by TamR, as do citrate, cis-aconitate and isocitrate, which are the substrate, intermediate and pr

300 rial isocitrate dehydrogenase (IDH2) to form isocitrate, which can then be isomerized to citrate.